2280:TADAWULAlmarai Company Analysis
Data as of 2026-07-15 - not real-time
SAR 46.64
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Almarai shares are trading at SAR 46.64, comfortably above the 20‑day (SAR 45.99), 50‑day (SAR 45.31) and 200‑day (SAR 44.65) moving averages, signaling a solid bullish bias. The MACD line sits at +0.42 above its signal (+0.40), producing a bullish histogram, while the RSI of 56 shows momentum is still in the neutral‑to‑positive zone. The price is anchored by a near‑term support at SAR 44.30 and faces resistance around SAR 47.30, leaving roughly a 2.7% upside in the immediate range. Market sentiment is extremely optimistic, as reflected by a Fear‑Greed Index of 92.5 (Extreme Greed) and a consensus “Strong Buy” from 17 analysts with a median target of SAR 58.
On the fundamentals side, Almarai delivered SAR 23.0 bn of revenue last year, growing 11% YoY, and generated a healthy operating margin of 13.9% and profit margin of 10.6%. Return on equity stands at 12.2% and cash flow from operations is robust at SAR 5.28 bn, supporting the current 2.47% dividend yield with a payout ratio of just 40%. However, the balance sheet carries a high debt‑to‑equity ratio of 69.7% and free cash flow is negative (‑SAR 1.66 bn), indicating that leverage and capital‑intensive investments remain a cautionary point. The discounted‑cash‑flow model values the company at SAR 62.36, implying roughly a 22% upside from today’s price and a 13% upside versus the analyst median target. Valuation multiples (PE ≈ 19, PB ≈ 2.2) are modest relative to peers, reinforcing the view that the stock is undervalued on a fair‑value basis. Given the low beta of 0.07 and a 30‑day volatility of about 20%, price swings are contained, while the defensive consumer‑staples sector buffers against macro‑economic shocks. In summary, the confluence of bullish technical signals, attractive dividend yield, solid earnings growth, and a sizable valuation upside makes Almarai a compelling buy in the near to medium term. Investors should still monitor debt levels and free‑cash‑flow trends, but the current risk‑adjusted profile remains favorable.
On the fundamentals side, Almarai delivered SAR 23.0 bn of revenue last year, growing 11% YoY, and generated a healthy operating margin of 13.9% and profit margin of 10.6%. Return on equity stands at 12.2% and cash flow from operations is robust at SAR 5.28 bn, supporting the current 2.47% dividend yield with a payout ratio of just 40%. However, the balance sheet carries a high debt‑to‑equity ratio of 69.7% and free cash flow is negative (‑SAR 1.66 bn), indicating that leverage and capital‑intensive investments remain a cautionary point. The discounted‑cash‑flow model values the company at SAR 62.36, implying roughly a 22% upside from today’s price and a 13% upside versus the analyst median target. Valuation multiples (PE ≈ 19, PB ≈ 2.2) are modest relative to peers, reinforcing the view that the stock is undervalued on a fair‑value basis. Given the low beta of 0.07 and a 30‑day volatility of about 20%, price swings are contained, while the defensive consumer‑staples sector buffers against macro‑economic shocks. In summary, the confluence of bullish technical signals, attractive dividend yield, solid earnings growth, and a sizable valuation upside makes Almarai a compelling buy in the near to medium term. Investors should still monitor debt levels and free‑cash‑flow trends, but the current risk‑adjusted profile remains favorable.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 8/10
Key Factors
- Price above all major moving averages
- Bullish MACD and supportive RSI
- Strong analyst consensus with upside potential
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- DCF fair value indicating ~22% upside
- 11% revenue growth and solid margins
- Sustainable 2.47% dividend yield
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- Defensive consumer staples positioning
- Brand strength and diversified product portfolio
- Undervalued valuation multiples despite high leverage
Key Metrics & Analysis
Financial Health
Revenue Growth11.00%
Profit Margin10.62%
P/E Ratio19.0
ROE12.23%
ROA4.78%
Debt/Equity69.66
P/B Ratio2.2
Op. Cash FlowSAR5.3B
Free Cash FlowSAR-1661924096
Technical Analysis
TrendBullish
RSI56.5
SupportSAR 44.30
ResistanceSAR 47.30
MA 20SAR 46.00
MA 50SAR 45.31
MA 200SAR 44.65
MACDBullish
VolumeIncreasing
Fear & Greed Index92.52
Valuation
Fair ValueSAR 62.36
Target PriceSAR 57.21
Upside/Downside22.65%
GradeUndervalued
TypeBlend
Dividend Yield2.47%
Risk Assessment
Beta0.07
Volatility20.48%
Sector RiskLow
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.